StormorkenH.The discovery of factor V: a tricky clotting factor. J Thrombosis Haemost2003;
1: 206–213.
2.
StormorkenH.Paul Arnor Owren. En medisinens mester [Paul Arnor Owren. A Master of Medicine].
Asker:
Tell forlag, 2000.
3.
BächliE.History of tissue factor. Br J Haematol2000;
110: 248–255.
4.
OwrenPA.Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet1947;
1: 446–444.
5.
OwrenPA.The Coagulation of Blood: Investigations on a New Clotting Factor.
Oslo:
JC Gundersen, 1947.
6.
OwrenPA.Long-term dicoumarol therapy in cardiovascular diseases. Acta Med Scand Suppl1953;
287: 46–48.
7.
BjerkelundCJ.The effect of long-term treatment with dicoumarol in myocardial infarction. A controlled clinical study. Acta Med Scand Suppl1957;
330: 1–212.
8.
MüllerC.Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand1938;
95: 75–84.
9.
OwrenPAHellemAJÖdegaardA.Linolenic acid for the prevention of thrombosis and myocardial infarction. Lancet1964;
284: 975–979.
10.
NatvigHBorchgrevinkCFDedichenJOwrenPASchiotzEHWestlundK.A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. Scand J Clin Lab Investig1968;
21: 1–20.
11.
StrømAJensenRA.Mortality from circulatory diseases in Norway 1940–1945. Lancet1951;
1: 126–129.
12.
Life Insurance Companies’ Institute for Medical Statistics at the Oslo City Hospitals.
Myocardial infarction. An epidemiological and prognostic study of patients from five departments of internal medicine in Oslo 1935–1949. Acta Med Scand1956;
315: 1–58.
13.
FranchiniMLiumbrunoGMBonfantiCLippiG.The evolution of anticoagulant therapy. Blood Transfusion2016;
14: 175–184.
14.
TimsonDJ.Dicoumarol: a drug which hits at least two very different targets in vitamin K metabolism. Curr Drug Targets2017;
18: 500–510.
15.
BjerkelundCJ.The method of administering dicoumarol. Lancet1953;
1: 260–265.
16.
LarsenØ.Doktorskole og medisinstudium. Det medisinske fakultet ved Universitetet i Oslo gjennom 200 år (1814–2014) [Doctoral school and medical studies. The medical faculty at the University of Oslo over 200 years (1814–2014)]. Michael Suppl2014;
15: 598.
17.
WrightISMarpleCDBeckDR.Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction. Am Heart J1948;
36: 801–815.
18.
CorbettMSWatsonJEastwoodA.Randomised trials comparing different healthcare settings: an exploratory review of the impact of pre-trial preferences on participation, and discussion of other methodological challenges. BMC Health Serv Res2016;
16: 589.
19.
MoodleyJNaidooSMoodleyJRamjeeG.Sharing of investigational drug among participants in the voice trial. AIDS Behav2016;
20: 2709–2714.
20.
CohenJ.The statistical power of abnormal – social psychological research: a review. J Abnormal Soc Psychol1962;
65: 145–153.
OtterstadJEBrosstadF.Utviklingen av den medisinske behandlingen av hjertepasienter [The development of the medical treatment of cardiac patients]. In: ForfangKRasmussenK, ed. Det norske hjerte. Norsk hjertemedisinsk historie [The Norwegian Heart. Norwegian Cardiology History].
Oslo:
Universitetsforlaget, 2007: 193–205.
30.
ChalmersTCMattaRJSmithHKunzlerA-M.Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med1977;
297: 1091–1096.
31.
BorchgrevinkCF.Long-term anticoagulant therapy in angina pectoris and myocardial infarction. Acta Med Scand1960;
359.
32.
PedersenT.Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarctionN Engl J Med1985;
313: 1055–1058.
33.
PedersenTKjekshusJBergKHaghfeltT.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;
344: 1383–1389.
34.
HurlenMAbdelnoorMSmithPErikssenJArnesenH.Warfarin, aspirin or both after myocardial infarction. N Engl J Med2002;
347: 969–974.
35.
SmithPArnesenHHolmeI.The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med1990;
323: 147–152.
36.
BønaaKHNjølstadIUelandPMSchirmerHTverdalASteigenT, et al.
Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med2006;
354: 1578–1588.
37.
International Anticoagulant Review Group.
Collaborative analysis of long-term anticoagulant administration after acute myocardial infarction. Lancet1970;
1: 203–209.
38.
LoeligerEA.Oral anticoagulation in the secondary prevention of myocardial infarction. Acta Med Scand Suppl1981;
651: 305–315.
39.
AnandSSYusufS.Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA1999;
282: 2058–2067.
40.
ConnorsJM.Testing and monitoring direct oral anticoagulants. Blood2018;
132: 2009–2015.
41.
HirschJ. Antithrombotic therapy. In: Kaushausky K and Berliner N, eds. 50 Years of Haematology. Research that Revolutionized Patient Care. Washington, DC: American Society of Hematology, 2008:28–31.
42.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet1988;
2: 349–360.
43.
BaigentCCollinsRApplebyPParishSSleightPPetoR.ISIS2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ1998;
316: 1337–1343.
44.
OASIS (The Organization to Assess Strategies for Ischemic Syndromes Investigators).
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol2001;
37: 475–484.
45.
CURE (The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigation).
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med2001;
345: 494–502.
46.
EikelboomJWConnollySJBoschJDagenaisGRHartRGShestakovskaO.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017;
377: 1319–1330.
47.
AtarDBodeCStuerzenbecherAVerheugtFWA.Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the last decade. Fund Clin Pharmacol2014;
28: 353–363.
48.
European Society of Cardiology Guidelines.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J2018;
39: 119–177.
49.
European Society of Cardiology Guidelines.
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J2021;
42: 1289–1367.
WadsworthDSullivanEJackyTSpragueTFeinmanHKimJ.A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther2021;
46: 560–570.
52.
AbildgaardUOrningO (2002). Christopher Juel Bjerkelund. Aftenposten 16 July 2002:
15.